When Prescribed Opioid Addiction Treatment Not Detected, Patients at Elevated Risk for Dangerous Drug Use

September 30, 2013

FOR IMMEDIATE RELEASE
September 30, 2013

When Prescribed Opioid Addiction Treatment Not Detected, Patients at Elevated Risk for Dangerous Drug Use

BALTIMORE – September 30, 2013 – Ameritox, the nation’s leader in pain medication monitoring, announced the results of a study today that reveals dangers facing the most vulnerable patients, those that are combating addiction.

Sublingual buprenorphine (i.e. Suboxone) is a medication used for the treatment of opioid dependence. Ameritox presented urine drug monitoring data at the American Academy of Pain Management meeting showing that approximately 95 percent of patients prescribed buprenorphine had evidence that they had  taken the medication.  The data also revealed that for the remaining 5 percent the likelihood of finding an opioid that was not  prescribed, or finding the illicit drug heroin, was four to five times greater than for the group where buprenorphine was detected.

“When you don’t find the prescribed Suboxone, you frequently find dangerous illicit drugs or non-prescribed medications, which is very concerning in a group of patients already diagnosed with an addictive disorder,” said Kathryn Bronstein, Ameritox Vice President of Medical Affairs.

Earlier this year, Ameritox released a National Prescription Drug Report showing the rate of illicit drug use within the chronic pain community to be at 11.1 percent. For comparison, illicit drugs are found in more than a quarter of patient samples that test negatively for sublingual buprenorphine.

Additional information on the methods, design and results of the research are available at Ameritox.com/research.

 About Ameritox
Ameritox is the nation’s leader in Pain Medication Monitoring SolutionsSM, offering specialized laboratory testing and reporting services. Ameritox’s expertise and innovative science provide physicians with the information and support they need to enhance and optimize the care of chronic pain patients. Monitoring through prescription drug testing can help physicians make more informed clinical decisions while also helping to reduce the possible risk of misuse, abuse or diversion of powerful medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on Facebook at facebook.com/ameritox, and on YouTube at www.youtube.com/ameritox.

© 2013 Ameritox Ltd. All rights reserved. Ameritox, Ameritox-Medication Monitoring Solutions, Rx Guardian, Rx Guardian INSIGHT and Rx Guardian CD are trademarks of Ameritox. Other trademarks are the property of their owners.